White Brook Capital, LLC on Rapid Micro Biosystems, Inc.
Thesis
White Brook argues Rapid Micro's share-price round trip reflects financing concerns rather than weakening execution. The company has achieved its operational and margin targets, while a MilliporeSigma distribution relationship is expected to bring additional customers and markets. New U.S. pharmaceutical factories should boost demand beginning around mid-2027, while stronger second-half activity could lower cash consumption. At roughly 1.1 times the midpoint of 2026 sales guidance on an enterprise-value basis, the fund sees upside if management rebuilds credibility and avoids another dilutive financing.
“We believe the share price implies a more pessimistic outlook for next year’s cash use than is likely.”
Key risks
- An earlier equity issuance damaged management credibility and raised concerns about further dilution.
- Cash use may not fall fast enough to avoid another capital raise.
- Year-end tax-loss selling could delay a rerating.
- New factory-driven revenue and distribution-partner expansion may arrive later than expected.